Eczema, often called atopic dermatitis, is a skin disease in which the skin gets dry, itchy, and inflammatory, resulting in redness, swelling, scaling, and crusting. Atopic dermatitis is most frequent in children under the age of one year. Atopic dermatitis has no known origin; however, it is believed to be due to genetics, immune system dysfunction, environmental exposure, and a problem with skin permeability. Arid climates are another significant cause of atopic dermatitis. This disease is not communicable and is easily identified by symptoms and signs such as skin redness and swelling. Hay fever and asthma are common symptoms of atopic dermatitis. Atopic dermatitis treatment includes calcineurin inhibitor ointment, steroid tablets, phototherapy, biologic therapies such as monoclonal antibodies, immunologic, and dietary adjustments in cases of food allergy.
To Get a Free Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/712
Atopic Dermatitis Drug Market Taxonomy
By End User;
- Hospitals
- Clinics
- Research Labs
By Route of Administration;
- Injectable
- Oral
- Topical
By Therapy;
- Photo Therapy
- Directed Therapy
Topical steroids and the development of novel drugs propel the global atopic dermatitis drug market growth over the forecast period
As topical steroids are used to treat atopic dermatitis, this sector accounts for the largest market share. A lukewarm bath accompanied by moisturizer application aids in treating atopic dermatitis. Atopic dermatitis is also treated with immunomodulators and pimecrolimus. According to the American Academy of Dermatology, around 28 million persons of all ages were affected by atopic dermatitis in the U. S. in 2016. The expected release of dupilumab, a monoclonal antibody in 2017 created by Regeneron Pharmaceuticals Inc. and Sanofi and the U.S. Food and Drug Administration approved it for the treating of atopic dermatitis, plays a significant role in the disease’s therapy, and boosts the global atopic dermatitis drug market over the forecast period. The U.S. Food and Drug Administration approved crisaborole ointment for treating mild atopic dermatitis in December 2016. When such drugs are released, the U.S. FDA places a black box warning on the labels of the prescribed drug to warn the public of the potential side effects. New product introductions shortly are expected to greatly fuel the global atopic dermatitis drug market growth over the forecast period. As there is a significant need for new medicines with high efficiency and safety, this market provides chances for major players involved in the development of new drugs and therapies. The major problems confronting the atopic dermatitis drug market include side effects, high treatment costs, and a lack of good and safe therapies, all of which hamper the global atopic dermatitis drug market growth over the forecast period.
To get Covid-19 Impact PDF Brouchure of this Report: https://www.coherentmarketinsights.com/insight/request-pdf/712
Developed regions support the growth of atopic dermatitis drug market
Geographically, the global atopic dermatitis drug market is divided into Europe, Latin America, North America, Africa, the Middle East, and The Asia Pacific. Owing to the rising prevalence of atopic dermatitis cases and substantial research and development investment in the production of atopic dermatitis drugs, North America accounts for the largest share in the global atopic dermatitis drug market. The rise in skin and food allergies has increased the number of infants with atopic dermatitis, fueling the global atopic dermatitis drug market growth over the forecast period. Following the Asia Pacific, Europe is the second-largest market for atopic dermatitis drugs. The Asia Pacific is an emerging market due to the incidences of atopic dermatitis and rising demand for drugs in developing economies such as China and India. In the coming years, the market is forecasted to grow significantly, boosting the global atopic dermatitis drug market growth over the forecast period.
Key Players in the Global Atopic Dermatitis Drug Market
Key market players adopt various methods, such as mergers and acquisitions, to get a large market share and a competitive advantage. Novartis AG acquired Ziarco in 2016, adding an oral atopic dermatitis drug to its product portfolio. In 2016, Pfizer acquired Anacor Pharmaceuticals, gaining access to crisaborole, a non-steroidal topical gel approved by the U.S. FDA for the treatment of atopic dermatitis. Major players in the global atopic dermatitis drug market include Astellas Pharma Inc., Bayer Healthcare, Novartis AG, Meda AB, and Valent Pharmaceutical Inc.
To Direct Purchase of this Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/712
Table of Contents:
- Research Objective and assumption
o Research Objectives
o Assumptions
o Abbreviations - Market Overview
o Report Description
• Market Definition and Scope
o Executive Summary
• Market Snippet By Product Type
• Market Snippet By Application
• Market Snippet By Technology
• Market Snippet By End User
• Market Snippet By Region
o Coherent Opportunity Map (COM) - Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
• Drivers
• Restraints
• Market Opportunities
o Technological Trends
o PEST Analysis
o Impact Analysis - Global Atopic Dermatitis Drug Market, By Product Type, 2021 – 2028 (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2028 (%)
• Y-o-Y Growth Analysis, 2021 – 2028
• Segment Trends
o Reagents & Consumables
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Software’s
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Instruments
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million) - Global Atopic Dermatitis Drug Market, By Application, 2021 – 2028 (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2028 (%)
• Y-o-Y Growth Analysis, 2021 – 2028
• Segment Trends
o Genomics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Proteomics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Diagnostics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Drug Discovery
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million) - Global Atopic Dermatitis Drug Market, By Technology, 2021 – 2028 (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2028 (%)
• Y-o-Y Growth Analysis, 2021 – 2028
• Segment Trends
o Microarrays
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Microfluidics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million) - Global Atopic Dermatitis Drug Market, By End User, 2021 – 2028 (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2028 (%)
• Y-o-Y Growth Analysis, 2021 – 2028
• Segment Trends
o Hospitals
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Diagnostic Labs
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Academic & Research Institutes
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Biotechnology & Pharmaceutical Companies
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837